Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells.

Abstract

Adoptive transfer of T cells expressing chimeric antigen receptors (CARs) has shown promising antitumor activity in early phase clinical studies, especially for hematological malignancies. However, most preclinical models do not reliably mimic human disease. We reasoned that developing an adoptive T-cell therapy approach for spontaneous osteosarcoma (OS) occurring in dogs would more closely reproduce the condition in human cancer. To generate CAR-expressing canine T cells, we developed expansion and transduction protocols that allow for the generation of sufficient numbers of CAR-expressing canine T cells for future clinical studies in dogs within 2 weeks of ex vivo culture. To evaluate the functionality of CAR-expressing canine T cells, we targeted HER2(+) OS. We demonstrate that canine OS is positive for HER2, and that canine T cells expressing a HER2-specific CAR with human-derived transmembrane and CD28.ζ signaling domains recognize and kill HER2(+) canine OS cell lines in an antigen-dependent manner. To reduce the potential immunogenicity of the CAR, we evaluated a CAR with canine-derived transmembrane and signaling domains, and found no functional difference between human and canine CARs. Hence, we have successfully developed a strategy to generate CAR-expressing canine T cells for future preclinical studies in dogs. Testing T-cell therapies in an immunocompetent, outbred animal model may improve our ability to predict their safety and efficacy before conducting studies in humans.

• Authors: Melinda Mata, Juan F Vera, Claudia Gerken, Cliona M Rooney, Tasha Miller, Catherine Pfent, Lisa L Wang, Heather M Wilson-Robles, Stephen Gottschalk
• Journal: Journal of immunotherapy (Hagerstown, Md. : 1997) (J Immunother) Vol. 37 Issue 8 Pg. 407-15 (Oct 2014) ISSN: 1537-4513 [Electronic] United States
• PMID: 25198528 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• CD28 Antigens
• Receptors, Antigen, T-Cell
• ERBB2 protein, human
• Receptor, ErbB-2

Topics

• Animals
• CD28 Antigens (genetics, metabolism)
• Cytotoxicity, Immunologic
• Disease Models, Animal
• Dogs
• Humans
• Immunotherapy, Adoptive (methods)
• K562 Cells
• Lymphocyte Activation
• Osteosarcoma (therapy)
• Receptor, ErbB-2 (immunology)
• Receptors, Antigen, T-Cell (genetics, metabolism)
• T-Cell Antigen Receptor Specificity
• T-Lymphocytes (immunology, transplantation)
• Transgenes (genetics)